Acrivon therapeutics announces initial patient dosing in phase 1 trial of acr-2316, a novel wee1/pkmyt1 inhibitor designed using ap3 for superior single-agent activity

- first patient dosed two quarters ahead of original timelines in acrivon phase 1 study to assess safety and tolerability of acr-2316

ACRV Ratings Summary

ACRV Quant Ranking